Tuesday, April 23, 2019 6:09:30 PM
that is a great post.
this was in the works for weeks and weeks.
company is preparing for fast track FDA designation.
what happened today was all shorting and panic selling.
and some profit taking.
over 17 million shares is the bought volume.
13.3 million shares is the sold volume.
this is not a selloff.
this is heavy shorting. shorts taking advantage of fools and the uninformed.
you also don't get $15 million from the institutions if you don't have a significant game changer on your hands.
they have around 10% institutional ownership.
those fund managers are a lot smarter than the average clown on the street.
you don't see them running.
what they have a significant discovery on their hands.
their data is what is going to drive this stock to around $3.50 to $4 on Thursday in my estimation.
but it will start running well ahead of the CC tomorrow.
it should be able to gap up and then run hard.
shorts are done. they cant drive it down anymore.
this was in the works for weeks and weeks.
company is preparing for fast track FDA designation.
what happened today was all shorting and panic selling.
and some profit taking.
over 17 million shares is the bought volume.
13.3 million shares is the sold volume.
this is not a selloff.
this is heavy shorting. shorts taking advantage of fools and the uninformed.
you also don't get $15 million from the institutions if you don't have a significant game changer on your hands.
they have around 10% institutional ownership.
those fund managers are a lot smarter than the average clown on the street.
you don't see them running.
what they have a significant discovery on their hands.
their data is what is going to drive this stock to around $3.50 to $4 on Thursday in my estimation.
but it will start running well ahead of the CC tomorrow.
it should be able to gap up and then run hard.
shorts are done. they cant drive it down anymore.
Recent MBRX News
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/27/2026 08:01:09 PM
- Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout • GlobeNewswire Inc. • 03/23/2026 12:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 12:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 12:45:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 12:35:12 PM
- Moleculin to Present at 38th Annual ROTH Conference • GlobeNewswire Inc. • 03/17/2026 01:05:00 PM
- Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study • GlobeNewswire Inc. • 03/11/2026 01:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/09/2026 07:58:05 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/27/2026 07:09:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2026 01:50:23 PM
- Moleculin shares slide sharply after warrant exercise deal • IH Market News • 02/19/2026 03:46:31 PM
- Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds • GlobeNewswire Inc. • 02/19/2026 01:39:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 09:31:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 01:20:16 PM
- Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30) • GlobeNewswire Inc. • 02/18/2026 01:20:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 01:35:16 PM
- Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin • GlobeNewswire Inc. • 02/17/2026 01:35:00 PM
- Moleculin Launches CEO Corner Platform to Share Strategic Insights • GlobeNewswire Inc. • 02/13/2026 01:32:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2026 04:55:04 PM
- Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial • GlobeNewswire Inc. • 02/05/2026 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/20/2026 01:00:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/13/2026 01:55:12 PM
- Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects • GlobeNewswire Inc. • 01/13/2026 01:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 01:36:11 PM
- Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs • GlobeNewswire Inc. • 01/12/2026 01:36:00 PM
